Caspase 7 Antibody - #DF6441

Fig. 5. Combination GSK-LSD1 + AQB pro- motes apoptosis by targeting BBC3 in vitro. (A) mRNA levels of BBC3 measured by qPCR after treatment 100 µM GSK-LSD1, 40 µM AQB, or 100 µM GSK-LSD1 + 40 µM AQB for 48 h. (B) Relative BBC3 mRNA levels after treat- ment with 100 µM GSK-LSD1, 40 µM AQB, or their combination after 12, 24, 48, or 72 h. (C) Relative BBC3 mRNA levels measured by qPCR after treatment with indicated concen- trations of AQB or GSK-LSD1 for 48 h. (D) Combination treatment effects on BBC3 mRNA levels at varied concentrations. (E) Western blot analysis of PUMA, Caspase 3, Caspase 7 after treatment with indicated concentrations of AQB for 48 h. (F) Western blot analysis of PUMA, Caspase 3, Caspase 7 after treatment with 200 µM GSK-LSD1, 80 µM AQB, or 200 µM GSK-LSD1 + 80 µM AQB for 48 h. (G) Apoptosis detection after 48 h of treatment with 200 µM GSK-LSD1, 80 µM AQB, or 200 µM GSK-LSD1 + 80 µM AQB. (H) Immunofluorescence assay for PUMA expression after the treatment with 100 µM GSK-LSD1, 40 µM AQB, or 100 µM GSK-LSD1 + 40 µM AQB for 48 h. Data are represented as mean ± s.d.; n = 3 indepen- dent experiments. ****P < 0.0001, ***P < 0.001, **P < 0.01, *P < 0.05.